Archive · 7 Sep 2026
Apollo Ingredients Plans Science-Backed Branded Nutraceutical Growth in India
Apollo Ingredients is an Indian company that sells ingredients to businesses making health and wellness products.
It does not mainly sell finished supplements directly to consumers.
Instead, it supplies ingredients that can be used in nutraceutical, pharmaceutical and wellness products.
The company wants these ingredients to be supported by research and clinical testing.
It also says quality and consistency are important for building customer trust.
In FY 2025-26, Apollo reported a much higher profit than in the previous year.
Its sales also grew, although its expenses increased as well.
The company believes growing interest in preventive healthcare could create more opportunities.
Apollo says it hopes to help India become an important center for nutraceutical innovation.
Apollo Ingredients Limited supplies branded nutraceutical ingredients to manufacturers in the nutraceutical, pharmaceutical and wellness sectors.
The company says its strategy centers on research, clinical validation and quality assurance.
Apollo reported FY 2025-26 net profit of ₹70.85 lakh, up from ₹9.75 lakh the previous year.
Net sales rose 59% to ₹490.24 lakh, while total expenses increased 38% to ₹407.84 lakh.
Director Lovely Mutreja said Apollo aims to build an innovation-led platform focused on clinically tested, science-backed ingredients.
- Who
- Apollo Ingredients Limited and its director, Lovely Mutreja.
- What
- The company outlined its strategy to build a science-backed, branded nutraceutical ingredients business and reported stronger FY 2025-26 financial results.
- When
- The announcement was dated September 7; the reported financial results cover FY 2025-26.
- Where
- New Delhi, India; the company targets domestic and international markets.
- Why
- Apollo aims to benefit from rising demand for preventive healthcare, functional nutrition and scientifically validated ingredients.
- Company
- Apollo Ingredients Limited
- Stock listing
- BSE: 503639
- FY 2025-26 net profit
- ₹70.85 lakh, compared with ₹9.75 lakh previously
- FY 2025-26 net sales
- ₹490.24 lakh, up from ₹307.49 lakh
- FY 2025-26 total expenses
- ₹407.84 lakh, up 38%
- Business model
- B2B supply of branded nutraceutical ingredients
- Strategic focus
- Research, clinical validation, quality assurance and product innovation